Russian peptide design programs
Russian programs that designed peptides to mimic neurotrophins, modified short glycine–proline sequences or studied marine peptides that act on ion channels.
Findings from selected studies
- Dilept compared with risperidone
In a 25-person psychiatric comparison, the WAIS-R coding task favored Dilept by 1.90 points. The negative-symptom score showed no significant advantage over risperidone.
Browse study findings by subject ↓
Closely related analogues share one card where that makes comparison clearer. Each family page separates its members, source types and findings. Code names in a patent are not a catalogue of proven therapies.
Three ways into short-peptide research
Reproduce part of a protein
NGF, BDNF, NT-3 and NT-4 mimetics test whether selected structural loops can reproduce particular signaling responses. Even small structural changes can alter the measured biological effect.
GK-2 versus GK-6 primary study ↗Trace an active fragment
Myelopeptides and glyprolins connect tissue fractions with defined sequences. Detecting a peptide, proposing its protein origin and demonstrating a physiological function are separate questions.
MP-4 isolation and cell research ↗Start from a drug’s structure
The Zakusov developers describe piracetam-inspired Noopept and sulpiride-inspired Dilept as a distinct approach. Their historical account belongs alongside the original experiments, not in place of them.
Developer design account ↗Ion-channel peptide research
These peptides act on different channels and can have opposite effects. Ms13-1 is a pain-provoking research probe; it should not be grouped with protective findings. M2IP is an international comparator.
| Peptide | Target | Research context |
|---|---|---|
| APHC peptides | TRPV1 | Channel modulation; experimental pain research |
| Ueq 12-1 | TRPA1 | A separate sea-anemone TRPA1 ligand |
| HCIQ2c1 | TRPA1 | Open-state stabilization and restricted hyperactivation; mouse pain and inflammation findings |
| Hcr ASIC peptides | ASIC1a | Inhibitory peptide research |
| Ms13-1 | ASIC1a | Positive modulation; induced pain-related behavior in mice |
| M2IP | TRPM2 | International comparator; inhibition and mouse ischemic-injury findings |
Channel assays and animal experiments do not establish clinical effectiveness or safety. Each profile links the relevant source and its review scope.
Explore the families
NGF mimetics: GK & GTS series ↗
Миметики ФРН
A family of experimental peptides designed from exposed loops of nerve growth factor. Related structures can differ in cell survival, differentiation and pain responses.
No human treatment trial assessed for this family
FAMILY RECORDBDNF mimetics: GSB, GBK & GTS ↗
Миметики BDNF
Small experimental mimetics of different BDNF loops, grouped for comparison of chemistry, signaling and behavioral results.
No human treatment trial assessed for this family
FAMILY RECORDNT-3 mimetics: GTS-301 & GTS-302 ↗
ГТС-301 / ГТС-302
A paired NT-3 research record comparing two loop-4 mimetics with different downstream signaling and animal pharmacology.
No human treatment trial assessed for this family
PEPTIDE RECORDGZS-411 ↗
ГЗС-411
A 2026 experimental dimeric dipeptide designed from NT-4 loop 1. Its currently linked findings are cell-based.
No human treatment trial assessed for this family
FAMILY RECORDCPG & GZK-111 ↗
ЦПГ / ГЗК-111
A grouped record for endogenous cyclo(Pro-Gly), its experimental linear precursor GZK-111 and the connection to Noopept metabolism.
No human treatment trial assessed for this family
FAMILY RECORDGlyprolins & PGP hybrids ↗
Глипролины
A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.
No human treatment trial assessed for this family
FAMILY RECORDMyelopid & MP-1–MP-6 ↗
Миелопид / миелопептиды
A marrow-peptide family separating the original mixture from defined isolates and later synthetic research. Each member needs its own evidence.
No human treatment trial assessed for this family
FAMILY RECORDSedatin & dermorphin analogues ↗
Седатин / аналоги дерморфина
A family of synthetic dermorphin-related peptides studied in tissue homeostasis, oxidative injury and opioid pharmacology.
No human treatment trial assessed for this family
FAMILY RECORDNALE & peptide G ↗
НАЛЭ
An experimental non-opiate leu-enkephalin analogue used to investigate cytoprotection apart from conventional opioid effects.
No human treatment trial assessed for this family
FAMILY RECORDGB-115 & CCK analogues ↗
ГБ-115
A synthetic CCK-4-related dipeptide derivative studied as Ranquilon in randomized human anxiety trials; related CCK-4 and stereochemical compounds are kept distinct.
Phase II (168), phase III (220), active-comparator phase IV (200), and earlier pilot reports
FAMILY RECORDLiberol / TRH research ↗
Либерол
An archival occupational-research record for the Liberol/TRH branch, covering historical human functional-reserve experiments.
Human dissertation material; original scan and study design pending
FAMILY RECORDBestim ↗
Бестим
A gamma-linked D-Glu/L-Trp dipeptide with immune-cell binding research and limited human adjunct-treatment reports. Distinct from Thymogen and Thymodepressin.
Human adjunct-treatment reports linked; allocation and independent effects remain uncertain
FAMILY RECORDImunofan ↗
Имунофан
A synthetic RDKVYR hexapeptide with cell, animal and human wound-related research. Historical Thymohexin names have conflicting sequence order.
A 69-patient diabetic-foot trial and a 28-patient ulcer report are linked; full appraisal remains pending
FAMILY RECORDGepon & ezrin-derived peptides ↗
Гепон
An ezrin-related peptide family with a patent identity trail, an uncontrolled human ulcerative-colitis report and preclinical experiments. Related fragments are separate research objects.
Uncontrolled 36-patient ulcerative-colitis report linked; no controlled benefit established
What changes in the existing map?
The CPG and GZK-111 profile now connects AMPA/TrkB work, IGF-1 experiments, rat metabolism, coagulation assays and the human stroke biomarker cohort. The 2026 Selank ischemia study remains a separate early gene-expression experiment in rats.
- Noopept: original CPG-metabolism evidence and the separate GZK-111 precursor program.
- Dilept: the psychiatric pilot, metabolite GZR-125 and animal withdrawal studies, kept separate from environmental testing.
- Semax and Selank: glyprolin design history, including a direct experiment showing that short PGP peptides did not reproduce Semax’s expression pattern.
- Dalargin: separate NALE and Sedatin branches, including the 2026 NOP-blockade follow-up.
- Thymogen and Thymohexin: Bestim binding and the Imunofan sequence distinction.
Sources still needed
Occupational adaptation: Cortexin and comparators
Pyatibrat’s 2016 dissertation listing identifies separate Metaprot, Cytoflavin, Cortexin and Gliatilin sections and a pharmacogenetic research program. Original tables and allocation details are still needed before extracting group-specific effect estimates or reconciling reported military cohorts.
Dissertation listing and excerpt ↗The existing 2007 environmental-chamber report concerns a different study. Dissertation and review summaries should not be counted as independent replication.
These leads remain visible without being presented as established mechanisms, new clinical indications or independent replications.
FMRFamide, FaRPs & peptide mixtures
The 1996 rat resuscitation citation and Krushinskaya’s dissertation on hemorrhage and hypobaric hypoxia identify the research program. The available sources leave exact sequences, mixture composition and experimental results unclear.
Indexed animal-study citation ↗
Dissertation source ↗Hydra morphogen & CRH fragments
PMH/Hydra head-activator analogues and Pro–Pro–Ile (CRH 2–4) remain acquisition targets. Historical sequence transcriptions and mammalian immunoreactivity require original analytical confirmation.
Cryptides and neighboring programs
MP-2/hemorphin relationships, spinorphin/tynorphin, GPE and hydroxyproline peptides need sequence-specific primary records. A common fragment motif alone does not establish origin, receptor action or clinical benefit.
Unresolved analogue libraries
A10/A17/A43 now have a transcribed sequence table, but the original scan remains needed. GB-101, GBK-108/201 and GK-2f need complete member-specific assay mapping. The 2026 NT-3 stroke citation, Myelopeptides monograph and proposed extended NT-4 library also require further recovery.
Other immune-peptide lineages
Likopid/GMDP and the historical Blastolysin trail are separate bacterial cell-wall research, not evidence for thymic or marrow peptides. Deltaran formulation research should remain under the existing DSIP record.
DSIP and formulation distinctions ↗Bibliography & source documents ↗
How Molekul assesses evidence ↗
Study findings by subject
80 source records
2021 · Comparison in people
Dilept versus risperidone in a 28-day psychiatric comparison
A WAIS-R coding task favored Dilept by 1.90 points in the authors’ analysis. The PANSS negative-symptom subscale showed no significant advantage over risperidone.
2017 · Comparison in people
Dose-ranging cognitive report from the 25-patient Dilept pilot
The report describes greater changes across WAIS measures at 200 mg/day. These 25 patients match the dose-finding cohort described in the 2020 paper.
2009 · Animal research
Dilept formulation and metabolite exposure in rats
Unformulated oral Dilept had less than 1% absolute bioavailability in rats. The tablet improved oral exposure, and two metabolites remained detectable in blood for more than four hours.
2026 · Randomized study in people
Ranquilon versus Afobazol for anxiety in neurasthenia and adjustment disorders: open randomized phase IV comparison
The open trial reported ≥50% HARS improvement in 63.3% (62 patients) with Ranquilon versus 49.0% (49 patients) with Afobazol at day 29 (p<0.043).
2007 · Animal research
CCK-4 dipeptide analogue design: opposite behavioral effects of L- and D-tryptophan derivatives
L-tryptophan derivatives showed anxiety-reducing effects, while D-tryptophan derivatives produced anxiety-like behavior. GB-115 was selected from the L-tryptophan series, with reported rat activity at 0.05–0.2 mg/kg.
1991 · Randomized study in people
Dose-ranging CCK-4 panic-challenge study in healthy volunteers
Panic attacks occurred after CCK-4 in 11%, 17% and 47% of challenges at 9, 25 and 50 micrograms, respectively; none occurred with placebo.
CCK-4 panic incidence · 11% / 17% / 47% across increasing doses; 0 with placebo
2022 · Animal research
Metabolism of a New Dipeptide Neuroprotector in Rats.
Four GZK-111 biotransformation products were identified. Ester hydrolysis and pathways producing phenylacetic acid and CPG were described.
2002 · Animal research
[Multicomponent antithrombotic effect of the neuroprotective prolyl dipeptide GVS-111 and its major metabolite cyclo-L-prolylglycine].
GVS-111 altered coagulation and fibrinolysis in experimental work. In-vitro CPG also showed antiaggregant activity; concentrations extending to 10⁻¹⁰ M were reported.
2023 · Review of earlier studies
Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions.
The review brings together cGP/IGF-1 associations and experimental intervention studies. Its stroke biomarker discussion includes the separately listed 2019 cohort.
2025 · Review of earlier studies
Neuropeptide Cyclo-Prolylglycine: Discovery, Pharmacological Effects, and Mechanism of Action
The authors discuss two proposed mechanisms: IGF-1 homeostasis and AMPA modulation with downstream neurotrophin signaling. The review connects the endogenous peptide with the Noopept research lineage.
2015 · Animal research
Dimeric dipeptide mimetics of the nerve growth factor Loop 4 and Loop 1 activate TRKA with different patterns of intracellular signal transduction.
GK-2 and GK-6 both increased TrkA phosphorylation, but GK-6 additionally recruited ERK, promoted PC12 differentiation and lowered rat pain thresholds. GK-2 favored AKT signaling in these assays and did not produce the same hyperalgesia.
2026 · Lab research
N-Isocaproyl-L-Arginylglycine Hexamethylenediamide, First Low-Molecular-Weight Mimetic of Neurotrophin-4: Design and Neuroprotective Activity.
GZS-411 activated TrkB and protected cultured cells against oxidative stress, glutamate toxicity and 6-hydroxydopamine. The study does not establish animal or human treatment effects.
2022 · Animal research
The First Dipeptide Mimetic of Neurotrofin-3: Design and Pharmacological Properties.
GTS-301 activated TrkC and TrkB, protected HT-22 cells in injury assays and showed antidepressant-like activity in a mouse forced-swim experiment.
2024 · Animal research
Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. The publisher’s 2025 erratum corrects an author’s surname, not experimental results.
2025 · Research record
Erratum to: Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.
The publisher corrects the second author’s surname to Mark A. Konstantinopolsky. The notice does not change experimental results and is not another experiment.
2025 · Animal research
Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302.
GTS-302 altered forced-swim, elevated-plus-maze and object-recognition outcomes in rodents, without changing hot-plate pain sensitivity in the reported tests.
2025 · Animal research
Analgesic Activity of the Low Molecular Weight Neurotrophin-3 Dipeptide Mimetic GTS-301.
GTS-301 increased rat tail-flick pain thresholds by about 20–30%, with a reported effect lasting at least 24 hours in this experiment. This endpoint is distinct from the GTS-302 hot-plate test.
2023 · Animal research
LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats.
After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.
2022 · Animal research
Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective Activity.
GZK-111 underwent extensive conversion to CPG in rats. CPG persisted more than twice as long in plasma and reached higher concentrations than the parent compound.
1996 · Laboratory analysis
Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain.
Chromatographic and mass-spectrometric methods identified CPG in rat brain. Synthetic CPG also altered passive-avoidance performance in rats. Endogenous detection does not establish supplementation benefit.
Endogenous brain CPG content · 2.8 ± 0.3 nmol/g wet brain
1997 · Animal research
The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.
Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.
2016 · Lab research
Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors.
CPG enhanced AMPA currents in rat cerebellar Purkinje cells. A proposed downstream BDNF mechanism requires distinction from the measured electrophysiological response.
2022 · Lab research
Neuroprotective Effect of the Neuropeptide Cycloprolylglycine Depends on AMPA- and TrkB-Receptor Activation.
AMPA and Trk receptor blockers prevented the reported CPG neuroprotective effect in cultured-cell experiments. Pharmacological blockade supports pathway involvement, not a fully resolved mechanism.
2004 · Lab research
Pyroglutamyl-asparagine amide normalizes long-term potentiation in rat hippocampal slices.
Pyroglutamyl-asparagine amide facilitated weakly induced long-term potentiation and countered ethanol-impaired potentiation in rat hippocampal slices. This separate piracetam-inspired dipeptide is not CPG.
2005 · Review of earlier studies
Natural and hybrid ("chimeric") stable regulatory glyproline peptides.
The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.
Methods and source ↗ · Glyprolins & PGP hybrids · Semax · Selank
2020 · Observational study
[The peptide analogue of neurotensin with antipsychotic and pro-cognitive effects: results of the pilot clinical trial].
A 25-person Dilept pilot reported psychiatric and cognitive improvement, most evident at 200 mg/day; it did not provide numerical symptom-score changes in its abstract.
2013 · Animal research
[The study of procognitive effect of the potential antipsychotic, Dilept and its main metabolite, GZR-125 at the novel objects recognition test in rats].
Dilept and its metabolite GZR-125 were compared in rat novel-object recognition experiments, extending the neurotensin-mimetic program beyond the parent compound.
2013 · Animal research
[Neurotensin NT (8- 13) dipeptide analog dilept increases the pain threshold and decreases the severity of morphine withdrawal syndrome in rats].
Dilept increased experimental pain thresholds and reduced morphine-withdrawal signs in rats. These findings are distinct from its small psychiatric pilot and occupational comparisons.
Pain threshold · 34% increase · p<0.01
2019 · Observational study
[Results of a clinical study of a new anxiolytic, a blocker of central cholecystokinin receptors].
A 31-person, 21-day uncontrolled GB-115 pilot reported improvements in anxiety, attention and sleep; it does not quantify an advantage over placebo or standard drugs.
2013 · Animal research
Anxiolytic activity of dipeptide GB-115 after oral administration.
Oral GB-115 changed anxiety-related behavior in rodents, with effects depending on strain and stress-response phenotype.
2012 · Animal research
Role of the cholecystokinin system in anxiolytic activity of dipeptide GB-115.
GB-115 countered some CCK-4-induced behavioral responses but not yohimbine-induced anxiety in C57Bl/6 mice, indicating model-dependent effects rather than universal anxiolysis.
2018 · Review of earlier studies
Novel Technologies for Dipeptide Drugs Design and their Implantation.
The developers distinguish drug-inspired peptide design (Noopept and Dilept) from mimicking peptide/protein turns (GB-115 and GK-2). This is a historical design framework, not evidence of a shared clinical effect.
Methods and source ↗ · NGF mimetics: GK & GTS series · CPG & GZK-111 · Noopept · Dilept · GB-115 & CCK analogues
2022 · Animal research
Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk
GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.
Methods and source ↗ · NGF mimetics: GK & GTS series · BDNF mimetics: GSB, GBK & GTS
2022 · Observational study
Clinical effects of GB-115 in patients with Generalized Anxiety Disorder
A conference post-hoc analysis of 25 patients reported lower anxiety and fatigue scores over 21 days. Its relationship to the earlier pilot must be resolved before treating it as independent evidence.
2025 · Animal research
HCIQ2c1 in mouse inflammation and macrophage assays
At 0.1 mg/kg, HCIQ2c1 approximately halved the paw volume increase after carrageenan at two hours in mice. The separate intravenous experiment also reported reduced inflammatory gene expression.
2025 · Animal research
Sea anemone Cys-ladder peptide Ms13-1 induces a pain response as a positive modulator of acid-sensing ion channel 1a.
Ms13-1 potentiated ASIC1a responses to acidic stimuli and produced prolonged pain-related behavior in mice. The peptide has a Cys-ladder fold and serves as a tool for studying channel function.
2024 · Animal research
Sea Anemone Kunitz Peptide HCIQ2c1: Structure, Modulation of TRPA1 Channel, and Suppression of Nociceptive Reaction In Vivo.
At 0.1 mg/kg intramuscularly, HCIQ2c1 increased mouse hot-plate response time from 16.3 to 21.8 seconds. The study also reported effects on rat TRPA1 and chemically induced mouse paw swelling.
Hot-plate response latency · 16.3 ± 1.0 seconds with saline vs 21.8 ± 1.7 seconds with HCIQ2c1 0.1 mg/kg IM
2026 · Animal research
Peptide Modulator of TRPV1 Channel Increases Long-Term Potentiation in the Hippocampus and Reduces Anxiety and Fear in Mice Under Acute Stress
APHC3 enhanced hippocampal long-term potentiation in mouse preparations and produced anxiolytic-like effects in acute-stress behavioral tests.
2020 · Lab research
APETx-Like Peptides from the Sea Anemone Heteractis crispa , Diverse in Their Effect on ASIC1a and ASIC3 Ion Channels
Hcr 1b-4 inhibited ASIC1a but potentiated ASIC3; Hcr 1b-3 inhibited both tested channels.
2017 · Animal research
New Disulfide-Stabilized Fold Provides Sea Anemone Peptide to Exhibit Both Antimicrobial and TRPA1 Potentiating Properties.
Ueq 12-1 potentiated TRPA1 and showed analgesic/anti-inflammatory activity in vivo, alongside moderate antibacterial activity.
2026 · Animal research
Spinorphin Ameliorates Nitroglycerin-Induced Migraine-Like Responses and Trigeminovascular Neuroinflammation Potentially Through Opioid Receptor-Mediated Mechanisms
Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.
2026 · Animal research
Spinorphin Attenuates Acute Experimental Seizures and Associated Neurochemical Alterations: Possible Involvement of Opioid Receptors
Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.
2021 · Lab research
Role of Amino Acid Arginine and Nitric Oxide in Mechanisms of Cytoprotective Effect of Non-Opiate Leu-Enkephalin Analogue In Vitro.
NALE and the C-terminal Gly comparator peptide G reduced oxidative-injury markers. NO-synthase inhibition did not remove protection, arguing against an essential role for terminal Arg or NO-synthase activation in this cell model.
NALE superoxide generation · 20.7% reduction
2026 · Lab research
Cytoprotective Effect of NOP Receptor Blockade in Primary Culture of Pulmonary Fibroblasts.
NALE retained cytoprotective effects during NOP-receptor blockade. Some combined measures improved further, so earlier proposals of NOP mediation remain unresolved rather than established.
2016 · Lab research
Cytoprotective Effect of Peptide Sedatin, an Agonist of μ/δ-Opioid Receptors, on Primary Culture of Pulmonary Fibroblasts of Albino Rats under Conditions of Oxidative Stress.
Sedatin preserved selected oxidative-stress and nuclear measures in rat pulmonary fibroblasts. Naloxone partially reduced these effects, supporting opioid involvement in this assay.
2009 · Animal research
Protective effect of dermorphin analogue sedatin on indomethacin-induced injury to the gastric mucosa.
Sedatin pretreatment reduced indomethacin-induced gastric injury in mice; the Arg-free comparator did not reproduce the same pattern.
2007 · Animal research
Effect of synthetic dermorphin analogues on tissue homeostasis in the myocardium of newborn albino rats.
Sedatin changed myocardial DNA-synthesis, nucleolar and oxidative measures in newborn rats. Its Arg-free analogue showed little effect in this experiment.
2019 · Lab research
Cytoprotective effect of non-opioid leu-enkephalin analogue in primary culture of pulmonary fibroblasts in oxidative stress
NALE reduced oxidative-stress and nucleolar changes in pulmonary fibroblasts. The paper explicitly gives Phe–D-Ala–Gly–Phe–Leu–Arg; its suggested NOP mechanism was a hypothesis.
2010 · Animal research
Morphogenetic activity of dermorphin and its analogues in different cell populations
The dissertation transcription identifies A10, A17, A43 and Sedatin as distinct synthetic analogues. Gastric and corneal DNA-synthesis responses differed across the tested peptides, arguing against a uniform tissue effect.
1999 · Lab research
Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays
Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.
[L-Ala²] analogue · 19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM
2000 · Animal research
Dalargin and liver function during acute hypoxia
The dissertation transcription reports longer survival in severe hypobaric hypoxia at testing times through 168 hours after ordinary intravenous administration and through 336 hours with erythrocyte-carrier delivery. Liver and oxidative-stress markers varied by delivery method and time.
2011 · Animal research
Protective activity of Mildronate, Dalargin and Picamilon in experimental stress
The dissertation examines three separate pharmacological approaches to experimental stress, including behavior, gastric injury and nonspecific cellular immunity. The comparative program connects opioid-peptide research with Picamilon and Mildronate.
1999 · Animal research
Post-resuscitation hemostasis correction with Dalargin and Mildronate
The Russian State Library verifies a 1999 experimental dissertation abstract on Dalargin and Mildronate in post-resuscitation hemostasis. A linked digital abstract is listed; efficacy and synergy claims require original-table review.
2023 · Comparison in people
Dalargin and oxidative stress in severe combined trauma: a prospective clinical study
Among 104 patients (38 Dalargin, 66 controls), the authors reported lower oxidative-stress markers and fewer ARDS/acute kidney injury events. Mortality and infectious complications were comparable; antioxidant activity remained below normal. Hospitalization was shorter among survivors receiving Dalargin.
Mortality · 8/38 (21.1%) versus 17/66 (25.8%) · p=0.6412; nonsignificant
2002 · Animal research
Receptor specificity of the antiarrhythmic effect of Dalargin and DADLE during myocardial reperfusion
The experimental report describes prevention of ventricular arrhythmias when Dalargin or DADLE was given before coronary reperfusion. It investigates opioid-receptor involvement rather than establishing a clinical antiarrhythmic treatment.
2019 · Animal research
Semax and immune activity in an experimental social-stress model
The authors reported that Semax shifted measures of cellular and humoral immunity and neutrophil phagocytosis toward control activity in the stressed animals.
2023 · Animal research
Semax and cytokines after experimental social stress in rats
In 50 rats, the authors reported that Semax shifted the measured cytokine panel toward control levels after experimental social stress.
Cytokine pattern with Semax · Reported shift toward control levels among IL‑1β, IL‑4, IL‑6, TNF‑α and TGF‑β1
2019 · Animal research
Semax and serum IL‑1β in stressed rats
Serum IL‑1β increased after social stress. The authors reported lower IL‑1β in stressed rats given Semax.
2019 · Animal research
Semax and thymus and spleen lipid peroxidation in stressed rats
The authors reported lower lipid-peroxidation markers in thymus and spleen homogenates from stressed rats that received Semax.
2006 · Animal research
Radiolabeled Semax in rat brain after intranasal dosing
At two minutes, 0.093% of administered radioactivity per gram was detected in brain. About 80% of that signal was identified as Semax.
2026 · Comparison in people
Changes in retinal light sensitivity and morphometry during surgical treatment of primary glaucoma with physiotherapeutic stimulation
After glaucoma surgery, a physiotherapy package including Semax electrophoresis improved visual-field mean deviation from −8.62 ± 1.86 to −4.33 ± 0.98 dB, with benefit maintained through six months. The comparison group received Semax nasal drops and returned to baseline by month three. Structural retinal measures and visual-field index did not differ significantly.
Visual-field mean deviation · −8.62 ± 1.86 → −7.03 ± 1.36 → −4.33 ± 0.98 dB · Baseline → after surgery → after added physiotherapy · p<0.01 after surgery; p<0.0001 after physiotherapy
2022 · Animal research
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats.
Selank reduced the overall withdrawal score by 39.6%, compared with 49.3% for diazepam. It also reduced several physical withdrawal signs. This is an animal-model finding, not a clinical withdrawal treatment.
2020 · Animal research
Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Treated with Selank.
Selank-treated rats had lower corticosterone and fewer stress-related changes in the colon wall. The study connects stress biology with tissue changes in the gut.
2019 · Animal research
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.
Selank improved object-recognition performance during alcohol withdrawal and prevented the ethanol-associated rise in BDNF in the hippocampus and frontal cortex. This finding concerns normalization in this model, not a general increase in BDNF.
2019 · Animal research
Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress.
Selank reduced stress-related liver-cell damage at all tested doses. The strongest reported effect occurred at the middle dose, 300 micrograms/kg; the response was not simply greater at higher doses.
2019 · Animal research
State of Colon Microbiota in Rats during Chronic Restraint Stress and Selank Treatment.
Stress shifted the balance of intestinal bacteria. The authors report that Selank restored the microbiota toward its usual composition; the abstract does not provide species-level changes or numerical effect sizes.
2026 · Animal research
Intranasal Semax Attenuates Behavioral and Cognitive Deficits in a Rat Model of LPS-induced Neuroinflammation — preprint
The preprint reports improvement in behavioral and cognitive measures following intranasal Semax in an LPS-induced inflammation model.
2025 · Lab research
Semax and ACTH(6–9)PGP in human microglial and neuronal cell cultures
After seven hours, Semax and ACTH(6–9)PGP each reduced IL-1β and IL-6 in LPS-stimulated HMC-3 cultures. The report gives the size of the LPS response and the direction of the peptide effects.
IL-1β and IL-6 in HMC-3 cultures · LPS alone raised IL-1β to 1.5× and IL-6 to 2.0× unstimulated levels. Each peptide lowered both cytokines versus LPS alone. · 7 hours · The authors report significant reductions with peptide treatment. Exact effect sizes and p-values are absent from the summary.
2026 · Comparison in people
[Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome].
The combined heliox and Semax electrophoresis group showed greater recovery of visual acuity and retinal sensitivity than the Semax nasal-drop group.
Combined treatment · Heliox: 21% oxygen, 79% helium · After 15 minutes, 1% Semax electrophoresis for 10 minutes; eight daily procedures starting postoperative day 5
2025 · Lab research
The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons.
Semax increased spontaneous calcium-event frequency in hippocampal CA1 neurons. It did not significantly change proton-stimulated calcium responses in cerebellar granule cells.
2025 · Animal research
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
The authors reported improved motor recovery and reduced oxidative stress and pyroptosis. Experiments proposed an Oprm1–USP18–FTO pathway.
2025 · Lab research
Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing.
Semax reduced copper-associated reactive oxygen species and amyloid-related cellular toxicity in the tested systems, consistent with copper binding and altered redox activity.
2015 · Comparison in people
Optimization of the treatment of anxiety disorders with selank
The authors report earlier symptom improvement and fewer unwanted effects with adjunctive Selank. Both groups received phenazepam.
2000 · Controlled study in people
Evaluation of therapeutic effect of new Russian drug Semax in optic nerve disease
A three-group optic-nerve report described faster visual recovery when Semax was added to neurotrophic and anti-inflammatory care, without numerical visual-acuity or field changes in its abstract.
2008 · Randomized study in people
Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia
The authors report similar anxiety changes with the two treatments and assess serum enkephalin metabolism.
2014 · Comparison in people
A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in anxiety disorders
At day 14 the anxiety subscore fell 26.3% with Selank vs 55% with phenazepam. A week after stopping therapy, the paper reported 17 vs 9 responders (p=0.037).
2001 · Lab research
Semax and Selank inhibit enkephalin-degrading enzymes from human serum
Both peptides and certain fragments inhibited peptide-degrading enzymes in laboratory assays.
Semax IC50 · 10 microM
2003 · Animal research
Selank and short peptides of the tuftsin family in regulation of adaptive behavior in stress
The experiments compare behavior across structurally related peptides and emotional-reactivity groups.
2016 · Animal research
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
The study reports changes in neurotransmission-related gene expression after Selank.
Changed genes at one hour · 45
2018 · Lab research
Peptide-based Anxiolytics: Molecular Aspects of Heptapeptide Selank Biological Activity
The authors examine GABA-binding modulation as a possible mechanistic explanation.